(Q37631962)

21 August 2017

1 reference

title

Progression of Parkinson's disease in the clinical phase: potential markers (English)

1 reference

21 August 2017

1 reference

3

Daniela Berg

2 references

21 August 2017

ORCID Public Data File 2021

Walter Maetzler

series ordinal

1

object named as

Walter Maetzler

1 reference

21 August 2017

Inga Liepelt

2

1 reference

21 August 2017

language of work or name

1 reference

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1158-1171

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of motor impairment and disability in Parkinson disease: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Rate of clinical progression in Parkinson's disease. A prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Functional decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of parkinsonian signs in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Longitudinal metric properties of disability rating scales for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Differential progression of motor impairment in levodopa-treated Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Effect of age and disease duration on parkinsonian motor scores under levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Clinical observations on the rate of progression of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Clinical correlates of action tremor in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A randomized controlled trial of the effects of weights on amplitude and frequency of postural hand tremor in people with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Dopa-sensitive and Dopa-resistant gait parameters in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Effects of cognitive challenge on gait variability in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Postural reactions to soleus muscle vibration in Parkinson's disease: scaling deteriorates as disease progresses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Freezing of gait in PD: prospective assessment in the DATATOP cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Motor blocks in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Freezing of gait in patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Gait festination in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Motor fluctuations in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Predictors of freezing in Parkinson's disease: a survey of 6,620 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of dysprosody in Parkinson's disease over time--a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Speech rate and rhythm in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Repetitive speech phenomena in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Prevalence and pattern of perceived intelligibility changes in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Dysphagia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Dementia and survival in Parkinson disease: a 12-year population study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

The association of incident dementia with mortality in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Prognosis of Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of motor and cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

The rate of cognitive decline in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Neuropsychological characteristics of preclinical dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

The effect of age of onset of PD on risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Demonstration of cognitive decline in Parkinson's disease using the Cambridge Cognitive Assessment (Revised) (CAMCOG-R).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Change in cognitive function in idiopathic Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A longitudinal study of neuropsychological change in individuals with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Which factors predict cognitive decline in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Course of cognitive decline in Parkinson's disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Cognitive dysfunction and dementia in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Relation between clinical characteristics of Parkinson's disease and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Cognitive decline in Parkinson's disease: a prospective longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Cognitive profile of patients with newly diagnosed Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Defining mild cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Predictors and course of health-related quality of life in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Prospective longitudinal assessment of hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Depression and Parkinson's disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Higher incidence of depression preceding the onset of Parkinson's disease: a register study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Depression in Parkinson's disease: clinical correlates and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

An estimate of the incidence of depression in idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Insomnia in Parkinson's disease: frequency and progression over time

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Parkinson's disease and sleepiness: an integral part of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Is fatigue an independent and persistent symptom in patients with Parkinson disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Determinants of autonomic dysfunction in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: autonomic symptom and demographic comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Sympathetic cardiovascular dysfunction in long-standing idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Circadian heart rate variability in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Ambulatory ECG and analysis of heart rate variability in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Evaluation of sympathetic skin response in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A longitudinal study of visuospatial discrimination in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progressive worsening of spatial and chromatic processing deficits in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progress of visual dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Analysis of olfactory function and the depth of olfactory sulcus in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

UPDRS activity of daily living score as a marker of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Measuring symptom change in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Changes in quality of life in people with Parkinson's disease left untreated at diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Predictors of weight loss in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Mini Nutritional Assessment in patients with Parkinson's disease: correlation between worsening of the malnutrition and increasing number of disease-years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Changes in network activity with the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Can we image premotor Parkinson disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Progressive loss of cardiac sympathetic innervation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A controlled, longitudinal study of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970291-1

7 January 2021

10.1016/S1474-4422(09)70291-1

Identifiers

DOI

1 reference

21 August 2017

1 reference